"Otorinolaryngologie a foniatrie" . . "RIV/61989592:15110/11:33116461" . . . . "Imunohistochemick\u00E1 exprese onkoproteinu EGFR a jej\u00ED prognostick\u00FD v\u00FDznam u karcinom\u016F slinn\u00FDch \u017El\u00E1z"@cs . "RIV/61989592:15110/11:33116461!RIV12-MSM-15110___" . . "Bakaj, Tom\u00E1\u0161" . "CZ - \u010Cesk\u00E1 republika" . "Sk\u00E1lov\u00E1, Alena" . . . "prognosis; salivary gland carcinoma; EGFR oncoprotein"@en . "7"^^ . "C\u00EDle: Zhodnocen\u00ED exprese onkoproteinu EGFR u karcinom\u016F slinn\u00FDch \u017El\u00E1z a jej\u00ED korelace s progn\u00F3zou, T st\u00E1diem prim\u00E1rn\u00EDho tumoru a v\u00FDskytem region\u00E1ln\u00EDch metast\u00E1z. Metody: Retrospektivn\u00ED imunohistochemick\u00E1 anal\u00FDza exprese EGFR onkoproteinu byla provedena u 76 karcinom\u016F za u\u017Eit\u00ED formalinem fixovan\u00E9, v parafinu zalit\u00E9 tk\u00E1n\u011B. Exprese byla hodnocena pomoc\u00ED histoskore, kombinuj\u00EDc\u00EDho intenzitu (\u0161k\u00E1la \u017E\u00E1dn\u00E1, slab\u00E1, st\u0159edn\u00ED, siln\u00E1) membranosn\u00ED reakce a procento pozitivn\u00EDch bun\u011Bk jako 0 (zcela bez nebo reakce u {10 % bun\u011Bk), 1+, 2+ a 3+ (slab\u00E1, st\u0159edn\u00ED, siln\u00E1 reakce u ? 10 % bun\u011Bk). Prognostick\u00E9 korelace byly provedeny u 55 pacient\u016F univari\u00E1tn\u00ED anal\u00FDzou k\u0159ivek n\u00E1dorov\u011B specifick\u00E9ho p\u0159e\u017Eit\u00ED dle Kaplan-Meiera a porovn\u00E1n\u00EDm pomoc\u00ED log-rank testu, a to ve 3 modech: I. 0 negativn\u00ED vs. 1+, 2+, 3 + positivn\u00ED. II. 0, 1+ negativn\u00ED vs. 2+ a 3 + positivn\u00ED. III. 0, 1+, 2+ negativn\u00ED vs. 3 + positivn\u00ED." . . "Hosti\u010Dka, L." . "2" . "5"^^ . . "Zapletalov\u00E1, Jana" . "Immunohistochemical Expression of EGFR Oncoprotein and Its Prognostic Significance in Salivary Gland Carcinomas"@en . "Bro\u017E, Martin" . . . . . "60" . . "203996" . "7"^^ . "V" . "C\u00EDle: Zhodnocen\u00ED exprese onkoproteinu EGFR u karcinom\u016F slinn\u00FDch \u017El\u00E1z a jej\u00ED korelace s progn\u00F3zou, T st\u00E1diem prim\u00E1rn\u00EDho tumoru a v\u00FDskytem region\u00E1ln\u00EDch metast\u00E1z. Metody: Retrospektivn\u00ED imunohistochemick\u00E1 anal\u00FDza exprese EGFR onkoproteinu byla provedena u 76 karcinom\u016F za u\u017Eit\u00ED formalinem fixovan\u00E9, v parafinu zalit\u00E9 tk\u00E1n\u011B. Exprese byla hodnocena pomoc\u00ED histoskore, kombinuj\u00EDc\u00EDho intenzitu (\u0161k\u00E1la \u017E\u00E1dn\u00E1, slab\u00E1, st\u0159edn\u00ED, siln\u00E1) membranosn\u00ED reakce a procento pozitivn\u00EDch bun\u011Bk jako 0 (zcela bez nebo reakce u {10 % bun\u011Bk), 1+, 2+ a 3+ (slab\u00E1, st\u0159edn\u00ED, siln\u00E1 reakce u ? 10 % bun\u011Bk). Prognostick\u00E9 korelace byly provedeny u 55 pacient\u016F univari\u00E1tn\u00ED anal\u00FDzou k\u0159ivek n\u00E1dorov\u011B specifick\u00E9ho p\u0159e\u017Eit\u00ED dle Kaplan-Meiera a porovn\u00E1n\u00EDm pomoc\u00ED log-rank testu, a to ve 3 modech: I. 0 negativn\u00ED vs. 1+, 2+, 3 + positivn\u00ED. II. 0, 1+ negativn\u00ED vs. 2+ a 3 + positivn\u00ED. III. 0, 1+, 2+ negativn\u00ED vs. 3 + positivn\u00ED."@cs . "[830A12A20772]" . "Imunohistochemick\u00E1 exprese onkoproteinu EGFR a jej\u00ED prognostick\u00FD v\u00FDznam u karcinom\u016F slinn\u00FDch \u017El\u00E1z" . "Immunohistochemical Expression of EGFR Oncoprotein and Its Prognostic Significance in Salivary Gland Carcinomas"@en . "1210-7867" . . "15110" . "St\u00E1rek, Ivo" . . "Imunohistochemick\u00E1 exprese onkoproteinu EGFR a jej\u00ED prognostick\u00FD v\u00FDznam u karcinom\u016F slinn\u00FDch \u017El\u00E1z"@cs . "Background: To investigate the expression of EGFR oncoprotein in salivary gland carcinomas and to correlate it with the prognosis, T stage of the primary and its cervical metastases. Methods: Immunohistochemistry for EGFR protein was performed in 76 carcinomas, using formalin-fixed paraffin-embedded sections. For the evaluation of reactivity of tumor cells, a histoscore combining membranous staining intensity (scala no reaction, weak, moderate, strong) with the percentage of positive cells, namely 0 (no reaction or reaction in {10 % cells), 1+, 2+, 3+ (weak, moderate, strong in ? 10 % of cells) was applied. Prognostic correlation was performed in a subset of 55 patients in three different modes: I. 0 negative vs. 1+, 2+, 3 + positive. II. 0, 1+ negative vs. 2+ and 3 + positive. III. 0, 1+, 2+ negative vs. 3 + positive. Univariate disease-specific survival curves were calculated by Kaplan-Meier method, the distributions were compared with the log-rank test."@en . . . "Imunohistochemick\u00E1 exprese onkoproteinu EGFR a jej\u00ED prognostick\u00FD v\u00FDznam u karcinom\u016F slinn\u00FDch \u017El\u00E1z" . . "Ku\u010Derov\u00E1, Ladislava" .